UNSPSC 51263110: Idropranolol

This classification denotes a beta-adrenergic blocking agent with the molecular formula C16H23NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5U6118QYHK, chemically known as 1-((5,6-dihydro-1-naphthyl)oxy)-3-(isopropylamino)-2-propanol but generally known as idropranolol, which bears US NIH Compound Identifier 163314. European Medicines Agency schedules Idropranolol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08122MIG.

UNSPSC 51263110 Idropranolol (Commodity) shows minimal recent state and local activity directly aligned with the code's pharmaceutical scope. The single recorded opportunity—Seminole County, Florida's IFB 60459723LAS, posted June 30, 2026—solicits Naloxone and Safe Drug Deactivation Systems rather than Idropranolol itself, indicating a mismatch between the code assignment and the actual products being procured. This suggests the code may be underutilized or misapplied in state and local procurement systems, or that Idropranolol purchases are not routinely tracked under this specific commodity designation. State and local health departments, counties, and community health agencies would typically be the issuing bodies for pharmaceutical procurements of this type, but the dataset reflects limited documented activity under this code in recent months.

Seminole County's opportunity is the sole recent record: an IFB for 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually, with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida, and a response deadline of July 26, 2023. The contract includes a two-year initial term with one-year renewal option, fixed-fee pricing, E-Verify compliance, and potential FEMA funding with associated federal regulatory requirements. Beyond this single Florida solicitation, the source provides no evidence of additional state or local Idropranolol or related pharmaceutical procurement activity, suggesting the code warrants monitoring rather than immediate pursuit unless your firm has existing relationships in Florida's health-department or county-level pharmaceutical supply channels.